Axinn Leads Alvogen to Victory in Hatch-Waxman Case for Generic Zohydro®
August 27, 2018
Axinn is pleased to announce that the United States District Court for the District of Delaware granted judgment to Alvogen Malta Operations, Ltd. (“Alvogen”) over patents related to Pernix Ireland Pain DAC and Pernix Therapeutics, LLC’s (“Pernix”) hydrocodone extended-release capsules, Zohydro®. Axinn was the lead trial counsel for Alvogen in the Hatch-Waxman Act case.
Pernix sued Alvogen for patent infringement over U.S. Patent Nos. 9,265,760 and 9,339,499, both of which are entitled, “Treating Pain in Patients with Hepatic Impairment,” under 35 U.S.C. § 271(e)(2). The case involved numerous, intricate legal issues that were presented in a three-day bench trial presided over by Judge William Bryson from the Federal Circuit Court of Appeals, who sat on the case by designation.
The Court found that the patent claims asserted by Pernix were invalid as obvious under 35 U.S.C. § 103, and for failure to satisfy the written description requirement of 35 U.S.C. § 112(a). The decision removes Pernix’s patents as a barrier to Alvogen bringing its lower-cost generic product to market more than a decade before the patents are set to expire.
The Axinn team was led by partners Matt Becker and Ted Mathias, with Thomas Hedemann.
The final judgment was filed August 24, 2018.
Press coverage:
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Axinn Attorneys Named to the 2025 Lawdragon 500 X – The Next Generation Guide
Awards & Recognitions
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Hanging in the Balance: Supreme Court Declines to Decide the Uninjured Class Member Question in Labcorp v. Davis
Axinn Viewpoints
Antitrust